

Alkylating agents

Sulfur Nitrogen mustard/ Nitrosurea
mustard 1)Meclorothamine

Given IV. Streptoazocin

is Becomes the unstable **aziridinium**
converted **ion** and then gives alkylated
into biopolymer.

**episul-
fonium
ion**

attacked
by
nucleo-
phile from
cells and
becomes
alkylated
biopol-
ymer.

2) Chlorambucil

Relatively stable; given oral.

Least toxic, long-acting.

3) Cyclophosphamide

Active orally and parenterally.

Both sulfur and nitrogen mustard are converted into unstable 3-membered (onium) intermediates that they act by.

Plant products

Vinca alkaloids Ixabepilone

Include vincristine, semisynthetic amide
vinblastine, analogue of the
vinrosidine, spindle poison,
vinleurosine Etophilon B.

1) Paclitaxel Has lactam in its
(taxol) structure providing
increased *in vivo*
stability.

MOA: spindle Uses: Metastatic
poison inhibiting breast cancer
mitosis.

Plant products (cont)

Uses: ttt of breast, ovarian & **aids-related kaposi sarcoma.**

Signal transduction (PK) inhibitors

Imatinib mesylate Sorafenib tosylate

MOA: Competitive MOA: Broad
inhibition of TK--> spectrum kinase
inducing **apoptosis** inhibitor
or non-dividing cells.

Uses: CML, GIST, Uses: renal cell
acute lymphoblastic carcinoma and
leukemia (+ve colon cancer
philadelphia chromo-
somes)

SE: thrombocytopenis, skin rash, N/V, SE: Skin rash,
pulmonary edema. HTN, fatigue,
increased risk of
bleeding & wound
healing time.

Advantage: Orally administered, better patient tolerability.

Disadvantage: Cardiotoxicity

Resistance to tyrosine kinase forms:

- Altering amino a' to stop binding
- Increasing kinase levels
- Drug is substrate to efflux transporter, BCRP.

Anti-metabolites

Pyrimidine Purine Folic a'
antimetabolites antime- antimetab-
tabolites olites

1) 5-FU 1) 6-MP 1)
Methotrexate

MOA: thymid- Is *in vivo* MOA:
ylate synthase converted dihydrofolate
inhibitor or into 6- reductase
incorporated thionos- inhibitor
into RNA & inate.
DNA.

Anti-metabolites (cont)

2) Uracil MOA: inhibits Uses:
mustard the rate-l- remission in
imiting step leukaemia
during purine and breast
synthesis. cancer
management.

Alkylating Uses:
agent.

MOA: - with methotrexate for
Damages lymphocytic leukemia.
DNA that
in take in
uracil.

Uses: - Immunosuppressive for UC,
Non-ho- psoriatic arthrits, systemic
dgkins lopus erythromatosis.
lymphoma

Allopurinol potentiates its
effect by inhibiting its metabo-
lism.

Miscellaneous compounds

Platinum complexes Synthetic retinoid
analog

1) Cisplatin 1) Bexarotene

MOA: Cross-links DNA MOA: binds to
causing DNA confor- activated retinoid
mational changes. X receptors in
skin.

Uses: **with bleomycin** Use: cutaneous
& **vinblastine** for T-cell lymphoma
metastatic testicular
tumors.

2) Carboplatin



Immunotherapy/monoclonal antibodies

**Block	**Flag	**Deliver
1) Trastuzumab	1) Rituximab	1) Brentuximab vedotin
Blocks HER-2 receptors to stop growth.	chimeric (hybrid) monoclonal antibody.	Delivers chemotherapy drugs inside tumor cells.
2) Bevacizumab	Flag malignant B lymphocytes with CD20 receptor for the immune cells.	
Blocks VEGF--> no new blood vessels.	Use: Non-Hodgkins B-cell lymphoma.	
MOA: targeted therapy by selective binding on receptor to--**		

Antibiotics

Anthracyclines	Actinomycin
1) Doxorubicin HCl	1) Bleomycin
MOA: intercalates into DNA causing indirect inhibition of topoisomerase II--> decreased RNA & DNA synthesis.	Has multiple heterocyclic rings and cytotoxic glycosides.
SE: Cardiotoxicity, release of hydroxyl and superoxide radicals.	MOA: Fragmentation of DNA.
2) Doxorubicin HCl	2) Mitomycin C
Uses: Acute leukaemia, Hodgkins's disease	3 anti-cancer functional gps: Quinone + Aziridine + Carbamate.

Antibiotics (cont)

MOA: cross-links double helical DNA

Unreactive in natural state--reduction--> Indol-hydroquinone (bifunctional alkylating agent)

Hormones

Testolactone	Tamoxifen	Letrozole
MOA: Aromatase inhibitor stopping estrogen synthesis from testosterone.	Non-steroidal agent with anti-estrogen properties.	MOA: Aromatase inhibitor
Uses: Breast cancer in post-menopausal women.	MOA: binds to estrogen receptors resulting in decreased DNA transcription.	Uses: locally advanced or metastatic breast cancer.
	Uses: breast cancer in post-menopausal women.	

